Ultime notizie per Fate Therapeutics (NASDAQ:FATE) Azioni

Fate Therapeutics

Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.

Fate Therapeutics Inc

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Fate Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FATE#NASDAQ">FATE</a>) with a Neutral and maintains $5 price target.

News

Price Target

Reiteration

Analyst Ratings

FATE

HC Wainwright & Co. Reiterates Neutral on Fate Therapeutics, Maintains $5 Price Target

Needham analyst Gil Blum reiterates Fate Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FATE#NASDAQ">FATE</a>) with a Hold.

Needham Reiterates Hold on Fate Therapeutics

Fate Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FATE#NASDAQ">FATE</a>) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.48) by 31.25 percent. The company reported quarterly sales of $6.80 million which beat the analyst consensus estimate of $1.41 million by 382.73 percent. This is a 628.83 percent increase over sales of $933.00 thousand the same period last year.

Earnings

Earnings Beats

Fate Therapeutics Q2 2024 Adj EPS $(0.33) Beats $(0.48) Estimate, Sales $6.80M Beat $1.41M Estimate

Shares of The Charles Schwab Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHW#NYSE">SCHW</a>) fell sharply during Tuesday's session following <a href="https://www.benzinga.com/quote/SCHW/earnings">second-quarter results.</a>
Charles Schwab said adjusted net income declined 2% Y/Y to $1.465 billion. Adjusted EPS fell 3% Y/Y to 73 cents, beating the consensus of 72 cents, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Charles Schwab shares dipped 7.5% to $69.42 on Tuesday.
Here are some other stocks moving in today&#8217;s mid-day session.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Yoshitsu Co., Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TKLF#NASDAQ">TKLF</a>) jumped 109% to $0.6437 after the company reported a year-over-year increase in FY24 financial results.</li>
<li>Silo Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SILO#NASDAQ">SILO</a>) shares climbed 95.4% to $2.12 after the company obtained an exclusive global license to develop, manufacture, and commercialize its Alzheimer&#8217;s drug.</li>
<li>Logistic Properties of the Americas (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LPA#NYSE">LPA</a>) shares climbed 53.8% to $23.71.</li>
<li>NaaS Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAAS#NASDAQ">NAAS</a>) gained 38% to $3.8503.</li>
<li>Virpax Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRPX#NASDAQ">VRPX</a>) gained 38% to $1.4799.</li>
<li>AEON Biopharma, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEON#NYSE">AEON</a>) shares rose 29.2% to $2.9450 after jumping around 63% on Monday.</li>
<li>Conduit Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDT#NASDAQ">CDT</a>) gained 27.3% to $0.3055 after declining over 8% on Monday.</li>
<li>AngioDynamics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGO#NASDAQ">ANGO</a>) surged 24.7% to $7.39 after the company reported better-than-expected fourth-quarter financial results and issued FY25 guidance.</li>
<li>KWESST Micro Systems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KWE#NASDAQ">KWE</a>) gained 22.8% to $0.4160</li>
<li>Zenvia Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZENV#NASDAQ">ZENV</a>) climbed 22.7% to $1.9634. The company announced that it entered into an agreement with Alliance Global Partners to offer and sell Class A common shares up to $20 million.</li>
<li>Locafy Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCFY#NASDAQ">LCFY</a>) rose 21% to $4.4150.</li>
<li>SciSparc Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPRC#NASDAQ">SPRC</a>) gained 20% to $1.0150.</li>
<li>Koss Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KOSS#NASDAQ">KOSS</a>) rose 19.8% to $10.45.</li>
<li>Alpha Technology Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATGL#NASDAQ">ATGL</a>) climbed 19.2% to $3.42.</li>
<li>Meiwu Technology Company Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WNW#NASDAQ">WNW</a>) shares rose 16.1% to $1.01 after surging around 15% on Monday.</li>
<li>NetSol Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTWK#NASDAQ">NTWK</a>) climbed 16% to $3.0501 as the company signed a $16 million agreement with a major automaker to revolutionize digital car buying and leasing experience in the United States.</li>
<li>Chegg, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHGG#NYSE">CHGG</a>) gained 15% to $3.6440. Morgan Stanley analyst Josh Baer upgraded Chegg from Underweight to Equal-Weight and lowered the price target from $6.5 to $3.25.</li>
<li>8&#215;8, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EGHT#NASDAQ">EGHT</a>) gained 13.3% to $2.8450. 8&#215;8. secured a $200 million term loan at reduced interest rate.</li>
<li>Fate Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FATE#NASDAQ">FATE</a>) gained 12.8% to $4.39.</li>
<li>Pacific Biosciences of California, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>) rose 12.8% to $1.8350. PacBio is expected to hold its quarterly conference call to discuss its second quarter financial results on Wednesday, Aug. 7.</li>
<li>Newegg Commerce, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEGG#NASDAQ">NEGG</a>) gained 11.8% to $1.14.</li>
<li>Harmony Gold Mining Company Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HMY#NYSE">HMY</a>) jumped 11.8% to $10.57</li>
<li>Sana Biotechnology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SANA#NASDAQ">SANA</a>) surged 11.7% to $7.11.</li>
<li>ServisFirst Bancshares, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SFBS#NASDAQ">SFBS</a>) climbed 10.8% to $78.60 after the company reported better-than-expected second-quarter financial result. Also, Piper Sandler maintained a Neutral rating on the stock and raised its price target from $63 to $70.</li>
<li>Match Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTCH#NASDAQ">MTCH</a>) rose 7.9% to $34.54 after Starboard Value sent a letter to the company outlining initiatives for improving growth, profitability and capital allocation.</li>
<li>Arvinas, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARVN#NASDAQ">ARVN</a>) gained 7.7% to $32.27.</li>
<li>Shopify Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHOP#NYSE">SHOP</a>) shares rose 7.3% to $68.92 after B of A Securities upgraded the stock from Neutral to Buy.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Cyngn Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYN#NASDAQ">CYN</a>) shares fell 22.1% to $7.15 after jumping 54% on Monday.</li>
<li>Autonomix Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMIX#NASDAQ">AMIX</a>) shares declined 21.4% to $1.08. Autonomix shares jumped 130% on Monday after the company entered into an agreement with RF Innovations to license intellectual property for its Apex 6 Radiofrequency Generator.</li>
<li>Zeo Energy Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZEO#NASDAQ">ZEO</a>) fell 18% to $3.23.</li>
<li>Clearmind Medicine Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMND#NASDAQ">CMND</a>) fell 16.7% to $1.85. Clearmind Medicine announced the FDA clearance for IND application of MEAI-based CMND-100 oral capsule.</li>
<li>Crown LNG Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGBS#NASDAQ">CGBS</a>) declined 15.8% to $2.65.</li>
<li>Funko, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FNKO#NASDAQ">FNKO</a>) shares fell 13.3% to $8.71.</li>
<li>Shapeways Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHPW#NASDAQ">SHPW</a>) fell 13.2% to $0.3010.</li>
<li>Vicinity Motor Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VEV#NASDAQ">VEV</a>) shares dipped 12.8% to $0.5581 after dipping 10% on Monday.</li>
<li>Trump Media &amp; Technology Group Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>) shares fell 8.7% to $37.04. Trump Media &amp; Technology Group shares jumped over 31% on Monday following the attempted assassination of Donald Trump.</li>
<li>Greenpro Capital Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRNQ#NASDAQ">GRNQ</a>) shares fell 8.5% to $1.08. Greenpro Capital shares surged around 35% on Monday after the company announced that its subsidiary, Green-X, secured over $100 million in digital assets.</li>
<li>Grom Social Enterprises, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GROM#NASDAQ">GROM</a>) shares declined 7.8% to $0.3945 after gaining around 10% on Monday.</li>
<li>Reddit, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>) fell 7.1% to $67.83 after Loop Capital downgraded the stock from Buy to Hold.</li>
<li>Eos Energy Enterprises, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EOSE#NASDAQ">EOSE</a>) fell 7% to $1.9150.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39792248/jim-cramer-says-if-you-sell-this-chinese-ev-stock-now-some-clown-will-be-real-posit">Jim Cramer Says If You Sell This Chinese EV Stock Now, &#8216;Some Clown&#8217; Will Be &#8216;Real Positive About It,&#8217; Wait Until &#8216;All That Stuff Happens</a><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39792248/jim-cramer-says-if-you-sell-this-chinese-ev-stock-now-some-clown-will-be-real-posit">&#8216;</a></li>
</ul>

Intraday Update

Markets

Movers

Trading Ideas

AEON

AMIX

ANGO

ARVN

ATGL

CGBS

CHGG

CMND

EGHT

EOSE

FNKO

GRNQ

GROM

KOSS

LCFY

MTCH

NAAS

NEGG

NTWK

PACB

RDDT

SANA

SCHW

SFBS

SHOP

SHPW

SILO

SPRC

TKLF

VRPX

ZENV

Why Charles Schwab Shares Are Trading Lower By Over 7%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

U.S. stocks were mostly higher, with the Dow Jones index gaining around 550 points on Tuesday.
Shares of UnitedHealth Group Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) rose sharply during Tuesday's session following a <a href="https://www.benzinga.com/news/earnings/24/07/39790051/unitedhealth-q2-earnings-revenue-and-eps-beat-lifts-cyberattack-impact-estimate-reaffirms-profit-ou">second-quarter earnings beat.</a>
The company reported adjusted EPS of $6.80, up from $6.14 a year ago, beating the consensus of $6.66, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. UnitedHealth&#8217;s revenues increased nearly $6 billion (+6.4% Y/Y) to $98.86 billion, beating the consensus of $98.34 billion, led by expansion in people served domestically at Optum and UnitedHealthcare.
UnitedHealth Group shares gained 5.7% to $544.96 on Tuesday.
Here are some other big stocks recording gains in today&#8217;s session.
<ul>
<li>Logistic Properties of the Americas (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LPA#NYSE">LPA</a>) shares surged 53.8% to $23.71.</li>
<li>AngioDynamics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGO#NASDAQ">ANGO</a>) shares gained 24.7% to $7.39 after the company reported better-than-expected fourth-quarter financial results and issued FY25 guidance.</li>
<li>Chegg, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHGG#NYSE">CHGG</a>) jumped 15% to $3.6440. Morgan Stanley analyst Josh Baer upgraded Chegg from Underweight to Equal-Weight and lowered the price target from $6.5 to $3.25.</li>
<li>8&#215;8, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EGHT#NASDAQ">EGHT</a>) rose 13.3% to $2.8450. 8&#215;8. secured a $200 million term loan at reduced interest rate.</li>
<li>Fate Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FATE#NASDAQ">FATE</a>) climbed 12.8% to $4.39.</li>
<li>Pacific Biosciences of California, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>) gained 12.8% to $1.8350. PacBio is expected to hold its quarterly conference call to discuss its second quarter financial results on Wednesday, Aug. 7.</li>
<li>Newegg Commerce, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEGG#NASDAQ">NEGG</a>) rose 11.8% to $1.14.</li>
<li>Harmony Gold Mining Company Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HMY#NYSE">HMY</a>) climbed 11.8% to $10.57</li>
<li>ServisFirst Bancshares, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SFBS#NASDAQ">SFBS</a>) gained 10.8% to $78.60 after the company reported better-than-expected second-quarter financial result. Also, Piper Sandler maintained a Neutral rating on the stock and raised its price target from $63 to $70.</li>
<li>Wheels Up Experience Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UP#NYSE">UP</a>) rose 10.3% to $3.98.</li>
<li>Janux Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JANX#NASDAQ">JANX</a>) jumped 9.7% to $47.69.</li>
<li>Novavax, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) rose 8.1% to $16.34.</li>
<li>Match Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTCH#NASDAQ">MTCH</a>) gained 7.9% to $34.54 after Starboard Value sent a letter to the company outlining initiatives for improving growth, profitability and capital allocation.</li>
<li>Arvinas, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARVN#NASDAQ">ARVN</a>) shares climbed 7.7% to $32.27.</li>
<li>Dream Finders Homes, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DFH#NYSE">DFH</a>) rose 7.5% to $30.29.</li>
<li>Shopify Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHOP#NYSE">SHOP</a>) shares gained 7.3% to $68.92 after B of A Securities upgraded the stock from Neutral to Buy.</li>
<li>Tempus AI, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>) rose 7% to $39.15. Tempus expanded immuno-oncology portfolio with the launch of AI-enabled, multimodal immune profile algorithmic tests.</li>
<li>Newell Brands Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWL#NASDAQ">NWL</a>) gained 6.7% to $6.70. Newell Brands is expected to release its second quarter 2024 earnings results on Friday, July 26.</li>
<li>The Scotts Miracle-Gro Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMG#NYSE">SMG</a>) rose 5.7% to $65.56.</li>
<li>Bank of America Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>) rose 5% to $43.99 following upbeat quarterly results.</li>
<li>American Airlines Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAL#NASDAQ">AAL</a>) gained 4.7% to $11.13.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/07/39790965/top-3-health-care-stocks-that-should-keep-you-up-at-night-this-quarter">Top 3 Health Care Stocks That Should Keep You Up At Night This Quarter</a></li>
</ul>

JANX

NVAX

UnitedHealth Posts Better-Than-Expected Earnings, Joins AngioDynamics, Bank of America  And Other Big Stocks Moving Higher On Tuesday

WIIM

Fate Therapeutics shares are trading lower gaining Monday following an analyst upgrade.

Across the recent three months, 9 analysts have shared their insights on Fate Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FATE#NASDAQ">FATE</a>), expressing a variety of opinions spanning from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Fate Therapeutics, revealing an average target of $6.11, a high estimate of $9.00, and a low estimate of $4.00. This current average has decreased by 6.0% from the previous average price target of $6.50. 
<img src="https://www.benzinga.com/files/images/story/2024/1718654425_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Fate Therapeutics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Edward Tenthoff</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$6.00</td>
<td>$4.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$5.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Bill Maughan</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$9.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Etzer Darout</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$6.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>David Nierengarten</td>
<td>Wedbush</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$5.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Edward Tenthoff</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$4.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>David Nierengarten</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$7.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>David Nierengarten</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$7.00</td>
<td>-</td>
</tr>
<tr>
<td>Tazeen Ahmad</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Underperform</td>
<td>$6.00</td>
<td>$2.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Fate Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Fate Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Fate Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Fate Therapeutics's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/FATE/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Fate Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Delving into Fate Therapeutics's Background</h2>
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
<h3>Fate Therapeutics's Financial Performance</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Negative Revenue Trend: Examining Fate Therapeutics's financials over 3 months reveals challenges. As of 31 March, 2024, the company experienced a decline of approximately -96.74% in revenue growth, reflecting a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Fate Therapeutics's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -2493.71% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Fate Therapeutics's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -12.08% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Fate Therapeutics's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -8.92%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.24.
<h2>Analyst Ratings: Simplified</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Expert Outlook: Fate Therapeutics Through The Eyes Of 9 Analysts

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Goldman Sachs analyst Susan Maklari upgraded the rating for Toll Brothers, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOL#NYSE">TOL</a>) from Sell to Neutral, while raising the price target from $112 to $124. Toll Brothers shares fell 1.2% to close at $119.32 on Friday. <a href="https://www.benzinga.com/quote/TOL/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Piper Sandler analyst Edward Tenthoff upgraded Fate Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FATE#NASDAQ">FATE</a>) from Neutral to Overweight and booted the price target from $4 to $6. Fate Therapeutics shares fell 4% to settle at $3.61 on Friday. <a href="https://www.benzinga.com/quote/FATE/analyst-ratings">See how other analysts view this stock.</a></li>
<li>B of A Securities analyst George Staphos upgraded the rating for Greif, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEF#NYSE">GEF</a>) from Neutral to Buy, while increasing the price target from $76 to $77. Greif shares fell 0.7% to settle at $60.73 on Friday. <a href="https://www.benzinga.com/quote/GEF/analyst-ratings">See how other analysts view this stock. See how other analysts view this stock.</a></li>
<li>Truist Securities analyst Bill Chappell upgraded Keurig Dr Pepper Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KDP#NASDAQ">KDP</a>) from Sell to Hold and boosted the price target from $27 to $34. Keurig Dr Pepper shares fell 0.1% to close at $34.04 on Friday. <a href="https://www.benzinga.com/quote/KDP/analyst-ratings">See how other analysts view this stock.</a></li>
<li>UBS analyst Michael Lasser upgraded the rating for Best Buy Co., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBY#NYSE">BBY</a>) from Neutral to Buy, while raising the price target from $85 to $106. Best Buy shares fell 0.6% to settle at $87.21 on Friday. <a href="https://www.benzinga.com/quote/BBY/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Check This Out: <a href="https://www.benzinga.com/news/24/06/39354679/this-analyst-with-86-accuracy-rate-sees-over-13-upside-in-alphabet-here-are-5-stock-picks-for-last-w">This Analyst With 86% Accuracy Rate Sees Over 13% Upside In Alphabet &#8211; Here Are 5 Stock Picks For Last Week From Wall Street&#8217;s Most Accurate Analysts</a>

Upgrades

This Best Buy Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday

Piper Sandler analyst Edward Tenthoff upgrades Fate Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FATE#NASDAQ">FATE</a>) from Neutral to Overweight and raises the price target from $4 to $6.

Piper Sandler Upgrades Fate Therapeutics to Overweight, Raises Price Target to $6

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-ratings/">analyst ratings page</a>.
<ul>
<li>Stifel cut the price target for Spire Global, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPIR#NYSE">SPIR</a>) from $24 to $20. Stifel analyst Erik Rasmussen maintained a Buy rating. Spire Global shares fell 6.8% to close at $11.34 on Wednesday. <a href="https://www.benzinga.com/quote/SPIR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Oppenheimer boosted the price target for Analog Devices, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADI#NASDAQ">ADI</a>) from $215 to $245. Oppenheimer analyst Rick Schafer maintained an Outperform rating. Analog Devices shares rose 1.8% to close at $215.75 on Wednesday. <a href="https://www.benzinga.com/quote/ADI/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Goldman Sachs cut Sagimet Biosciences Inc.. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMT#NASDAQ">SGMT</a>) price target from $27 to $23. Goldman Sachs analyst Andrea Tan maintained a Buy rating. Sagimet Biosciences shares rose 5.5% to close at $4.62 on Wednesday. <a href="https://www.benzinga.com/quote/SGMT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>HC Wainwright &amp; Co. slashed the price target for Fate Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FATE#NASDAQ">FATE</a>) from $7 to $5. HC Wainwright &amp; Co. analyst Raghuram Selvaraju maintained a Neutral rating. Fate Therapeutics shares gained 0.5% to close at $4.24 on Wednesday. <a href="https://www.benzinga.com/quote/FATE/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird cut Accenture plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACN#NYSE">ACN</a>) price target from $372 to $345. Baird analyst David Koning maintained a Neutral rating. Accenture shares gained 0.5% to close at $308.52 on Wednesday. <a href="https://www.benzinga.com/quote/ACN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Needham boosted Zebra Technologies Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZBRA#NASDAQ">ZBRA</a>) price target from $352 to $370. Needham analyst James Ricchiuti maintained a Buy rating. Zebra Technologies shares rose 0.9% to close at $323.87 on Wednesday. <a href="https://www.benzinga.com/quote/ZBRA/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Mizuho raised the price target for Portland General Electric Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/POR#NYSE">POR</a>) from $42 to $45. Mizuho analyst Anthony Crowdell maintained a Neutral rating. Portland General Electric shares rose 0.8% to close at $44.64 on Wednesday. <a href="https://www.benzinga.com/quote/POR/analyst-ratings">See how other analysts view this stock.</a></li>
<li>B of A Securities raised Alibaba Group Holding Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) price target from $99 to $103. B of A Securities analyst Eddie Leung maintained a Buy rating. Alibaba shares gained 1.9% to close at $80.99 on Wednesday. <a href="https://www.benzinga.com/quote/BABA/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Keybanc raised monday.com Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNDY#NASDAQ">MNDY</a>) price target from $275 to $280. Keybanc analyst Jackson Ader maintained an Overweight rating. monday.com shares jumped 21.4% to close at $220.72 on Wednesday. <a href="https://www.benzinga.com/quote/MNDY/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Truist Securities cut Occidental Petroleum Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXY#NYSE">OXY</a>) price target from $84 to $69. Truist Securities analyst Neal Dingmann downgraded the stock from Buy to Hold. Occidental Petroleum shares climbed 0.5% to close at $63.38 on Wednesday. <a href="https://www.benzinga.com/quote/OXY/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Check This Out: <a href="https://www.benzinga.com/news/24/05/38869663/wall-streets-most-accurate-analysts-say-hold-these-3-real-estate-stocks-delivering-high-dividend-yie">Wall Street&#8217;s Most Accurate Analysts Say Hold These 3 Real Estate Stocks Delivering High-Dividend Yields</a>

BABA

MNDY

SGMT

SPIR

ZBRA

Alibaba To Rally Over 13%? Here Are 10 Top Analyst Forecasts For Thursday

HC Wainwright &amp; Co. analyst Raghuram Selvaraju maintains Fate Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FATE#NASDAQ">FATE</a>) with a Neutral and lowers the price target from $7 to $5.

HC Wainwright & Co. Maintains Neutral on Fate Therapeutics, Lowers Price Target to $5

Canaccord Genuity analyst Bill Maughan maintains Fate Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FATE#NASDAQ">FATE</a>) with a Buy and lowers the price target from $11 to $9.

Canaccord Genuity Maintains Buy on Fate Therapeutics, Lowers Price Target to $9

BMO Capital analyst Etzer Darout maintains Fate Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FATE#NASDAQ">FATE</a>) with a Market Perform and lowers the price target from $7 to $6.

BMO Capital Maintains Market Perform on Fate Therapeutics, Lowers Price Target to $6

Wedbush analyst David Nierengarten maintains Fate Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FATE#NASDAQ">FATE</a>) with a Neutral and lowers the price target from $7 to $5.

Wedbush Maintains Neutral on Fate Therapeutics, Lowers Price Target to $5

Piper Sandler analyst Edward Tenthoff maintains Fate Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FATE#NASDAQ">FATE</a>) with a Neutral and lowers the price target from $7 to $4.

Piper Sandler Maintains Neutral on Fate Therapeutics, Lowers Price Target to $4

Fate Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FATE#NASDAQ">FATE</a>) reported quarterly losses of $(0.47) per share which met the analyst consensus estimate. This is a 147.37 percent decrease over losses of $(0.19) per share from the same period last year. The company reported quarterly sales of $1.925 million which beat the analyst consensus estimate of $1.114 million by 72.76 percent. This is a 96.74 percent decrease over sales of $58.980 million the same period last year.

Fate Therapeutics Q1 2024 GAAP EPS $(0.47), Inline, Sales $1.925M Beat $1.114M Estimate

Fate Therapeutics Treats First Lupus Patient In Phase 1 Study Of FT819 CAR T-Cell Therapy

8 analysts have expressed a variety of opinions on Fate Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FATE#NASDAQ">FATE</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $7.25, a high estimate of $10.00, and a low estimate of $6.00. This current average has increased by 81.25% from the previous average price target of $4.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1715011238_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
A comprehensive examination of how financial experts perceive Fate Therapeutics is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Nierengarten</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$7.00</td>
<td>-</td>
</tr>
<tr>
<td>David Nierengarten</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$7.00</td>
<td>-</td>
</tr>
<tr>
<td>Tazeen Ahmad</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Underperform</td>
<td>$6.00</td>
<td>$2.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$7.00</td>
<td>-</td>
</tr>
<tr>
<td>Michael Ulz</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$7.00</td>
<td>$3.00</td>
</tr>
<tr>
<td>Etzer Darout</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$7.00</td>
<td>$6.00</td>
</tr>
<tr>
<td>Peter Lawson</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$10.00</td>
<td>$6.00</td>
</tr>
<tr>
<td>David Nierengarten</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Neutral</td>
<td>$7.00</td>
<td>$3.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Fate Therapeutics. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Fate Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Fate Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Fate Therapeutics's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/FATE/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Fate Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind Fate Therapeutics</h2>
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
<h3>Fate Therapeutics: A Financial Overview</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Decline in Revenue: Over the 3 months period, Fate Therapeutics faced challenges, resulting in a decline of approximately -96.22% in revenue growth as of 31 December, 2023. This signifies a reduction in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -2632.58%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Fate Therapeutics's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -11.44%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -8.4%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.28, Fate Therapeutics adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>How Are Analyst Ratings Determined?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Forecasting The Future: 8 Analyst Projections For Fate Therapeutics

Wedbush analyst David Nierengarten reiterates Fate Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FATE#NASDAQ">FATE</a>) with a Neutral and maintains $7 price target.

Wedbush Reiterates Neutral on Fate Therapeutics, Maintains $7 Price Target

Off-the-shelf, CD19-targeted CAR NK Cell Product Candidate Drives Rapid and Deep Depletion of SLE Donor CD19+ B cells &nbsp;
ADR Technology Incorporated into FT522 Induces Functional Persistence and Eliminates Alloreactive Host Immune Cells in SLE Donor PBMCs
SAN DIEGO, May 03, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FATE#NASDAQ">FATE</a>), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that a late-breaking abstract featuring preclinical data from its FT522 program for autoimmune diseases will be featured at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting, being held in&nbsp;Baltimore, Maryland&nbsp;on&nbsp;May 7-11, 2024.
FT522 is the Company's CD19-targeted, iPSC-derived CAR NK cell product candidate that incorporates its novel alloimmune defense receptor (ADR) technology, which is designed to increase the potency of off-the-shelf cell therapy and enable treatment without administration of conditioning chemotherapy to patients. At the ASGCT conference, the Company will present multiple preclinical studies displaying the function of FT522 using peripheral blood mononuclear cells (PBMCs) sourced from unmatched donors with systemic lupus erythematosus (SLE). These preclinical data demonstrate rapid and deep B-cell depletion, enhanced functional persistence, and elimination of alloreactive host immune cells, indicating that FT522 may deliver therapeutic benefit to patients with autoimmune diseases without requiring administration of conditioning chemotherapy.
Late-breaking abstracts are available on the&nbsp;<a href="https://www.globenewswire.com/Tracker?data=oo2DDUWSz8Ny2LxrME2ZYSAeD2RSDnj-oDTaupcJlOQwFY5hvRVbPT2Y6RIFaKyA4Qj_FAF43StHJbEO5ZHzG-nqXPY19pSWZor84_2lzCF2mALG5PEL6I3VCge-lMbp">ASGCT Annual Meeting&nbsp;website</a>. Presentation details are as follows:
Presentation FT522: A CAR NK Cell with the Unique Ability to Target Multiple Pathogenic Cell Types and Circumvent Lympho-conditioning in Systemic Autoimmunity Late-Breaking Abstract Number: LBA-35 Session: Late-Breaking Abstracts Location: Exhibit Hall Presentation Date / Time: Thursday, May 9, 2024 12:00 PM

Biotech

General

Fate Therapeutics Announces Presentation Of FT522 Preclinical Data For Autoimmune Diseases In Late-breaking Abstract At ASGCT Annual Meeting; ADR Technology Incorporated Into FT522 Induces Functional Persistence And Eliminates Alloreactive Host Immune Cells In SLE Donor PBMCs

Barclays analyst Peter Lawson maintained a Buy rating on Fate Therapeutics (FATE – Research Report) today and set a price target of $10.00. The com...

Fate Therapeutics (FATE) Receives a Buy from Barclays

Needham analyst Gil Blum has maintained their neutral stance on FATE stock, giving a Hold rating yesterday. Gil Blum has given his Hold rating due ...

Fate Therapeutics: A Hold Rating Amid Early Stage Pipeline and Financial Outlook

In a report released today, Edward Tenthoff from Piper Sandler reiterated a Buy rating on Fate Therapeutics (FATE – Research Report), with a price ...

Piper Sandler Keeps Their Buy Rating on Fate Therapeutics (FATE)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Fate Therapeutics (FATE – Research Report), Achiev...

Analysts' Opinions Are Mixed on These Healthcare Stocks: Fate Therapeutics (FATE), Achieve Life Sciences (ACHV) and Kezar Life Sciences (KZR)

In a report released yesterday, Etzer Darout from BMO Capital maintained a Hold rating on Fate Therapeutics (FATE – Research Report), with a price ...

Fate Therapeutics: Market Perform Rating Amidst Anticipated Data and Pipeline Progress

Stifel Nicolaus analyst Benjamin Burnett maintained a Hold rating on Fate Therapeutics (FATE – Research Report) on August 16 and set a price target...

Fate Therapeutics (FATE) Gets a Hold from Stifel Nicolaus

Leerink Partners analyst Daina Graybosch has maintained their bullish stance on FATE stock, giving a Buy rating on August 14. Daina Graybosch has g...

Fate Therapeutics' Promising Outlook: Buy Rating on Innovative Cell Therapy Programs FT819 and FT522

Fate Therapeutics (FATE – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Robert Burns from ...

Fate Therapeutics: Hold Rating Amid Financial Stability and Upcoming Milestones

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on PROCEPT BioRobotics (PRCT – Research Report) and F...

Analysts Offer Insights on Healthcare Companies: PROCEPT BioRobotics (PRCT) and Fate Therapeutics (FATE)

Fate Therapeutics (FATE) has issued an update. Fate Therapeutics, Inc. has updated its indemnification agreements for directors and officers, enhan...

Fate Therapeutics Strengthens Legal Safeguards for Leadership

ACHV

PRCT

Press Releases

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

FATE SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Fate Therapeutics, Inc. (NASDAQ: FATE) and Encourages Long-Term FATE Investors to Contact the Firm

Management

Fate Therapeutics Appoints Neely Mozaffarian, MD, PhD, FACR, to its Board of Directors

Fate Therapeutics Reports Second Quarter 2024 Financial Results and Business Updates

Fate Therapeutics to Present at 2024 Cantor Global Healthcare Conference

Legal

Kaskela Law LLC Announces Shareholder Investigation of Fate Therapeutics, Inc. (NASDAQ: FATE) and Encourages Long-Term FATE Shareholders to Contact the Firm

Comments

Fate Therapeutics

Notizie

Ultime notizie per Fate Therapeutics (NASDAQ:FATE) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO